

Jiankun Lyu

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2615396/publications.pdf>

Version: 2024-02-01

13
papers

5,105
citations

759233

12
h-index

1058476

14
g-index

17
all docs

17
docs citations

17
times ranked

11413
citing authors

#	ARTICLE	IF	CITATIONS
1	Property-Unmatched Decoys in Docking Benchmarks. <i>Journal of Chemical Information and Modeling</i> , 2021, 61, 699-714.	5.4	48
2	Drug-induced phospholipidosis confounds drug repurposing for SARS-CoV-2. <i>Science</i> , 2021, 373, 541-547.	12.6	148
3	A practical guide to large-scale docking. <i>Nature Protocols</i> , 2021, 16, 4799-4832.	12.0	206
4	Structures of the β_2 receptor enable docking for bioactive ligand discovery. <i>Nature</i> , 2021, 600, 759-764.	27.8	113
5	Structure of a Hallucinogen-Activated Gq-Coupled 5-HT _{2A} Serotonin Receptor. <i>Cell</i> , 2020, 182, 1574-1588.e19.	28.9	270
6	A SARS-CoV-2 protein interaction map reveals targets for drug repurposing. <i>Nature</i> , 2020, 583, 459-468.	27.8	3,542
7	Ultra-large library docking for discovering new chemotypes. <i>Nature</i> , 2019, 566, 224-229.	27.8	595
8	Selectivity Challenges in Docking Screens for GPCR Targets and Antitargets. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6830-6845.	6.4	31
9	Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- <i>d</i>]pyrimidine-2,4(1 <i>H</i>),3 <i>H</i> -diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 5609-5622.	6.4	27
10	Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5- <i>d</i>][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors. <i>Scientific Reports</i> , 2017, 7, 3830.	3.3	11
11	Discovery and Rational Design of Pteridin-7 <i>H</i> -one-Based Inhibitors Targeting FMS-like Tyrosine Kinase 3 (FLT3) and Its Mutants. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 6187-6200.	6.4	28
12	Discovery of peptide inhibitors targeting human programmed death 1 (PD-1) receptor. <i>Oncotarget</i> , 2016, 7, 64967-64976.	1.8	42
13	Antiproliferative and apoptosis-inducing activities of novel naphthalimide- α -cyclam conjugates through dual topoisomerase (topo) I/II inhibition. <i>Bioorganic and Medicinal Chemistry</i> , 2015, 23, 5672-5680.	3.0	23